A Single Center, Randomized, Open-Label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-Week Period
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2013
At a glance
- Drugs Adefovir; GX 110
- Indications Hepatitis B
- Focus Adverse reactions
- 03 Aug 2012 Actual end date (1 Dec 2010) added as reported by ClinicalTrials.gov.
- 01 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2008 Official Title amended as reported by ClinicalTrials.gov.